Bausch Health Companies (BHC)
Market Price (6/6/2026): $5.375 | Market Cap: $2.0 BilSector: Health Care | Industry: Pharmaceuticals
Bausch Health Companies (BHC)
Market Price (6/6/2026): $5.375Market Cap: $2.0 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% Attractive yieldFCF Yield is 49% Low stock price volatilityVol 12M is 50% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Geriatric Care. | Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -111% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 974% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -65% Key risksBHC key risks include [1] its substantial debt burden, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Attractive yieldFCF Yield is 49% |
| Low stock price volatilityVol 12M is 50% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Geriatric Care. |
| Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -111% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 974% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -65% |
| Key risksBHC key risks include [1] its substantial debt burden, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Bausch Health Companies (BHC) stock has lost about 10% since 2/28/2026 because of the following key factors:
1. Significant Non-Cash Goodwill Impairment Charge in Fiscal Q1 2026.
Bausch Health reported a substantial GAAP net loss attributable to the company of $1,423 million in fiscal Q1 2026, primarily due to a $1,426 million goodwill impairment charge. This non-cash charge, explicitly linked to an outcome from a Red Sea clinical trial, significantly impacted the reported profitability, overshadowing positive adjusted metrics.
2. Fiscal Q1 2026 Earnings Per Share Miss.
Despite reporting consolidated revenues of $2.52 billion that exceeded analysts' expectations, Bausch Health's adjusted earnings per diluted share (non-GAAP) of $0.78 for fiscal Q1 2026 fell short of the consensus estimate of $0.81. This earnings per share miss, even with revenue growth, likely contributed to investor concern.
Show more
Stock Movement Drivers
Fundamental Drivers
The -9.4% change in BHC stock from 2/28/2026 to 6/5/2026 was primarily driven by a -11.5% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6052026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.93 | 5.37 | -9.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10,266 | 10,531 | 2.6% |
| P/S Multiple | 0.2 | 0.2 | -11.5% |
| Shares Outstanding (Mil) | 372 | 373 | -0.3% |
| Cumulative Contribution | -9.4% |
Market Drivers
2/28/2026 to 6/5/2026| Return | Correlation | |
|---|---|---|
| BHC | -9.4% | |
| Market (SPY) | 7.8% | 43.6% |
| Sector (XLV) | -4.1% | 47.2% |
Fundamental Drivers
The -15.4% change in BHC stock from 11/30/2025 to 6/5/2026 was primarily driven by a -19.1% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6052026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.35 | 5.37 | -15.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10,029 | 10,531 | 5.0% |
| P/S Multiple | 0.2 | 0.2 | -19.1% |
| Shares Outstanding (Mil) | 371 | 373 | -0.4% |
| Cumulative Contribution | -15.4% |
Market Drivers
11/30/2025 to 6/5/2026| Return | Correlation | |
|---|---|---|
| BHC | -15.4% | |
| Market (SPY) | 8.5% | 37.0% |
| Sector (XLV) | -2.1% | 35.6% |
Fundamental Drivers
The 18.5% change in BHC stock from 5/31/2025 to 6/5/2026 was primarily driven by a 10.5% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6052026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.53 | 5.37 | 18.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9,731 | 10,531 | 8.2% |
| P/S Multiple | 0.2 | 0.2 | 10.5% |
| Shares Outstanding (Mil) | 370 | 373 | -0.9% |
| Cumulative Contribution | 18.5% |
Market Drivers
5/31/2025 to 6/5/2026| Return | Correlation | |
|---|---|---|
| BHC | 18.5% | |
| Market (SPY) | 26.6% | 20.6% |
| Sector (XLV) | 17.4% | 33.3% |
Fundamental Drivers
The -34.6% change in BHC stock from 5/31/2023 to 6/5/2026 was primarily driven by a -48.1% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6052026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.21 | 5.37 | -34.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8,150 | 10,531 | 29.2% |
| P/S Multiple | 0.4 | 0.2 | -48.1% |
| Shares Outstanding (Mil) | 363 | 373 | -2.5% |
| Cumulative Contribution | -34.6% |
Market Drivers
5/31/2023 to 6/5/2026| Return | Correlation | |
|---|---|---|
| BHC | -34.6% | |
| Market (SPY) | 83.4% | 29.4% |
| Sector (XLV) | 25.8% | 33.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BHC Return | 33% | -77% | 28% | 0% | -14% | -24% | -75% |
| Peers Return | 30% | 8% | 3% | 13% | 25% | 11% | 125% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| BHC Win Rate | 50% | 25% | 50% | 42% | 42% | 33% | |
| Peers Win Rate | 58% | 57% | 45% | 50% | 60% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| BHC Max Drawdown | -33% | -84% | -42% | -51% | -46% | -37% | |
| Peers Max Drawdown | -19% | -24% | -25% | -20% | -25% | -16% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABBV, JNJ, PFE, LLY, VTRS. See BHC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/5/2026 (YTD)
How Low Can It Go
| Event | BHC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -33.6% | -18.8% |
| % Gain to Breakeven | 50.7% | 23.1% |
| Time to Breakeven | 80 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -28.7% | -7.8% |
| % Gain to Breakeven | 40.2% | 8.5% |
| Time to Breakeven | 42 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.5% | -9.5% |
| % Gain to Breakeven | 45.9% | 10.5% |
| Time to Breakeven | 109 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -21.9% | -6.7% |
| % Gain to Breakeven | 28.0% | 7.1% |
| Time to Breakeven | 5 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -50.9% | -33.7% |
| % Gain to Breakeven | 103.9% | 50.9% |
| Time to Breakeven | 307 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.7% | -19.2% |
| % Gain to Breakeven | 60.5% | 23.8% |
| Time to Breakeven | 326 days | 105 days |
In The Past
Bausch Health Companies's stock fell -33.6% during the 2025 US Tariff Shock. Such a loss loss requires a 50.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BHC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -33.6% | -18.8% |
| % Gain to Breakeven | 50.7% | 23.1% |
| Time to Breakeven | 80 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -28.7% | -7.8% |
| % Gain to Breakeven | 40.2% | 8.5% |
| Time to Breakeven | 42 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.5% | -9.5% |
| % Gain to Breakeven | 45.9% | 10.5% |
| Time to Breakeven | 109 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -21.9% | -6.7% |
| % Gain to Breakeven | 28.0% | 7.1% |
| Time to Breakeven | 5 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -50.9% | -33.7% |
| % Gain to Breakeven | 103.9% | 50.9% |
| Time to Breakeven | 307 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.7% | -19.2% |
| % Gain to Breakeven | 60.5% | 23.8% |
| Time to Breakeven | 326 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -67.8% | -3.7% |
| % Gain to Breakeven | 210.5% | 3.9% |
| Time to Breakeven | 416 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -40.1% | -6.8% |
| % Gain to Breakeven | 66.8% | 7.3% |
| Time to Breakeven | 29 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -40.1% | -17.9% |
| % Gain to Breakeven | 66.9% | 21.8% |
| Time to Breakeven | 336 days | 123 days |
In The Past
Bausch Health Companies's stock fell -33.6% during the 2025 US Tariff Shock. Such a loss loss requires a 50.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bausch Health Companies (BHC)
AI Analysis | Feedback
Here are 1-3 brief analogies for Bausch Health Companies (BHC):
-
A diversified healthcare company, similar to a smaller Johnson & Johnson, with a focus on eye care, gastrointestinal, and dermatological products.
-
Imagine an eye care specialist like Alcon, combined with a pharmaceutical company developing treatments for gut and skin conditions.
AI Analysis | Feedback
- Bausch + Lomb Products: This segment offers a wide range of vision care products, ophthalmic surgical devices, and ophthalmic pharmaceuticals.
- Salix Gastroenterology Products: These are specialized pharmaceutical products primarily focused on treating gastroenterological conditions in the United States.
- Ortho Dermatologics Products: The company provides pharmaceutical products specifically for various dermatological conditions in the United States.
- Solta Medical Aesthetic Devices: This includes medical devices used for aesthetic procedures, distributed internationally.
- Diversified Pharmaceutical Products: This category covers pharmaceutical products for neurology and other therapeutic classes.
- Generic and OTC Products: The company manufactures a variety of generic pharmaceutical products and over-the-counter health products.
- Dentistry Products: Bausch Health also offers products related to dental health.
AI Analysis | Feedback
Bausch Health Companies Inc. (BHC) primarily sells its pharmaceutical, medical device, and over-the-counter (OTC) products to other companies rather than directly to individual consumers.
Its major customers are typically large healthcare distributors, retail pharmacy chains, hospitals, and other healthcare providers who then distribute or administer the products to end-users. The primary major customers can be categorized as:
- Wholesale Pharmaceutical Distributors: These companies are crucial intermediaries that purchase pharmaceuticals and medical devices from manufacturers like BHC and distribute them to pharmacies, hospitals, clinics, and other healthcare facilities. Major examples include:
- AmerisourceBergen Corp. (ABC)
- Cardinal Health, Inc. (CAH)
- McKesson Corporation (MCK)
- Retail Pharmacy Chains: Large pharmacy retailers, sometimes supplied directly by manufacturers or through distributors, are significant customers for OTC and prescription medications. Examples include:
- CVS Health Corporation (CVS)
- Walgreens Boots Alliance, Inc. (WBA)
- Hospitals, Clinics, and Healthcare Providers: For specialized pharmaceuticals, surgical products, medical devices (e.g., ophthalmic and aesthetic devices), and dentistry products, BHC sells to hospitals, surgical centers, ophthalmology clinics, dermatology practices, and dental offices. These are numerous and varied entities, typically purchasing through distributors or group purchasing organizations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Thomas J. Appio, Chief Executive Officer
Thomas J. Appio was appointed Chief Executive Officer of Bausch Health Companies Inc. in May 2022. He initially joined the organization in 2010 as the Managing Director for China at Bausch + Lomb. Before his tenure at Bausch + Lomb, Mr. Appio dedicated 23 years to Schering-Plough, where he held a diverse range of leadership and operations responsibilities across various countries and regions.
Jean-Jacques Charhon, Executive Vice President, Chief Financial Officer
Jean-Jacques Charhon joined Bausch Health as Executive Vice President and Chief Financial Officer in August 2024. Prior to this role, he served as Executive Vice President and Chief Financial Officer for Signant Health. Mr. Charhon possesses over 25 years of financial leadership experience, having held positions at both public and private companies, including General Electric, Hewlett Packard, Novartis, and Purdue Pharma.
Seana Carson, Executive Vice President, General Counsel
Seana Carson joined Bausch Health in November 2006 and has served as Executive Vice President, General Counsel since May 2022. Her previous roles within the company include Senior Vice President, Head of Legal International, and over 12 years as Senior Vice President and Chief Compliance Officer. Ms. Carson began her career as an Associate with the Canadian legal firm Ogilvy Renault LLP (now part of Norton Rose Fulbright).
Mirza Dautbegovic, Senior Vice President, Chief Operating Officer
Mirza Dautbegovic joined Bausch Health in 2017 as Vice President, International Finance. In this role, he was responsible for leading the company's finance function across all markets outside the U.S. Before joining Bausch Health, Mr. Dautbegovic spent more than 14 years at Tyco International (later Johnson Controls), where he held various leadership positions within multiple business segments and at the enterprise level.
Kathleen Fitzpatrick, Executive Vice President, Chief Human Resources and Communications Officer
Kathleen Fitzpatrick joined Bausch Health in 2019, initially as Vice President, Human Resources, where she focused on leading the company's HR efforts outside the United States and collaborating with international business leaders, manufacturing, and global functions. Prior to her time at Bausch Health, Ms. Fitzpatrick accumulated over 20 years of experience with Honeywell, serving in roles of increasing responsibility across several business units and countries.
AI Analysis | Feedback
The key risks to Bausch Health Companies (BHC) primarily revolve around its substantial debt burden, the impending loss of exclusivity for a major revenue-generating drug, and ongoing legal and regulatory challenges.
- High Debt Burden and Refinancing Risk: Bausch Health carries a significant amount of debt, which remains a primary concern for investors and analysts. The company reported total debt of approximately $21.5 billion as of the third quarter of 2024, with a high debt-to-capital ratio of 85% and leverage of about 7x. This substantial debt burden can limit the company's ability to invest in research and development, pursue strategic acquisitions, or expand into new markets. Upcoming debt maturities, particularly in the 2025-2028 period, add pressure and present significant refinancing risk.
- Loss of Exclusivity for Xifaxan and Generic Competition: Xifaxan (rifaximin) is identified as a "crown jewel" and a critical revenue driver for Bausch Health, particularly within its Salix segment, accounting for approximately 80% of Salix's revenues. The impending loss of exclusivity (LOE) for Xifaxan, with potential generic entry expected as early as 2027-2028, poses a significant threat to the company's revenue streams and market position. The pharmaceutical industry is characterized by intense competition, and the entry of generic competitors could lead to a rapid erosion of market share and pricing power for Xifaxan.
- Litigation and Regulatory Environment: Bausch Health faces ongoing legal and regulatory risks. These include past securities fraud allegations stemming from its history as Valeant Pharmaceuticals, which led to significant settlements. More recently, the company has been involved in multistate antitrust investigations and settlements regarding alleged collusion in the generic drug market. Additionally, potential government investigations and lawsuits, as well as the impact of Medicare drug price negotiations under the Inflation Reduction Act (particularly for Xifaxan starting in 2026), present further financial and strategic risks. The ongoing process of potentially separating Bausch + Lomb also carries legal implications and uncertainties regarding proceeds.
AI Analysis | Feedback
The U.S. Inflation Reduction Act (IRA) of 2022 introduces drug price negotiation provisions for certain high-cost, single-source drugs within the Medicare program. This represents a clear emerging threat to Bausch Health Companies, as it fundamentally alters the pricing model for established pharmaceutical products. Given BHC's portfolio of branded and diversified pharmaceutical products across segments like Salix (gastroenterology), Bausch + Lomb (ophthalmic pharmaceuticals), and others, key revenue-generating drugs could become subject to government price negotiations. This shift could lead to reduced revenues and profit margins for affected products, diverging significantly from the prior market-based pricing system in the U.S. for these types of drugs.
AI Analysis | Feedback
Bausch Health Companies Inc. (BHC) operates in several key therapeutic areas with substantial addressable markets globally and in the U.S. Below are the estimated addressable market sizes for its main products and services, where available:
Eye Health (Bausch + Lomb Segment)
- The global ophthalmology market was estimated at approximately USD 72.80 billion in 2023 and is projected to reach around USD 134.74 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2023 to 2033.
- The global vision care market was valued at USD 41.17 billion in 2022 and is expected to reach USD 57.96 million by 2030, exhibiting a CAGR of 4.23% during the forecast period of 2023-2030. Another estimate places the global vision care market size at USD 75.76 billion in 2025, projected to reach USD 95.78 billion by 2034, with a CAGR of 2.64% from 2026-2034. Asia Pacific holds the largest market share in vision care.
- The global advanced ophthalmology technologies market was estimated to be worth USD 7.94 billion in 2024 and is anticipated to reach USD 18.5 billion by 2035, growing at a CAGR of 7.99% from 2025–2035. North America is projected to be the fastest-growing region in this market.
Gastroenterology (Salix Segment)
- The overall global gastrointestinal market (including pharmaceuticals, medical devices, and OTC products) was US $69.50 billion in 2024 and is projected to reach US $111.60 billion by 2031, with a CAGR of 7.00%.
- The global gastrointestinal therapeutics market, specifically for drugs, was valued at USD 41.94 billion in 2025 and is estimated to grow to USD 53.96 billion by 2031, at a CAGR of 4.29%. North America accounted for a 38.61% revenue share in 2025.
- The U.S. gastrointestinal therapeutics market generated a revenue of USD 12.27 billion in 2022 and is expected to reach US$14.69 billion by 2030, at a CAGR of 2.3% from 2023 to 2030.
- The global prescription gastrointestinal drugs market size was valued at USD 28.93 billion in 2024 and is projected to grow to USD 42.66 billion by 2034, exhibiting a CAGR of 5.8%. The U.S. accounts for a dominant share in this market.
Dermatology (Ortho Dermatologics Segment)
- The global dermatological therapeutics market is projected to be USD 49.54 billion in 2025 and is expected to reach USD 83.59 billion by 2031, growing at a CAGR of 9.12% from 2026 to 2031.
- The U.S. dermatological drugs market size was estimated at USD 8.32 billion in 2024 and is projected to grow at a CAGR of 9.7% from 2025 to 2030, reaching USD 14.48 billion by 2030.
- The global dermatology drugs market size is valued at USD 51.37 billion in 2026 and is projected to reach USD 96.49 billion by 2034, with a CAGR of 8.20% during 2026–2034. North America accounted for the highest market share in 2025, with a valuation of USD 24.04 billion.
Medical Aesthetic Devices (Solta Medical, part of Ortho Dermatologics and International Rx)
- The global medical aesthetics market was worth over USD 6.25 billion in 2024 and is projected to exceed USD 8.64 billion by 2034, growing at a CAGR of 3.29% from 2025–2034. Another source indicates the global medical aesthetics market is valued at US$40.70 billion by 2031, growing at a CAGR of 13.0%.
- The global medical aesthetic devices market is estimated to be valued at USD 20.62 billion in 2025 and is expected to reach USD 46.76 billion by 2032, exhibiting a CAGR of 12.4% from 2025 to 2032.
- The United States aesthetic devices market size is estimated at USD 11.17 billion in 2026 and is forecast to climb to USD 16.65 billion by 2031, growing at an 8.32% CAGR over 2026-2031.
- The U.S. medical aesthetic devices market size was valued at USD 6.32 billion in 2024 and is expected to be worth around USD 16.54 billion by 2034, growing at a CAGR of 10.1% during the forecast period from 2025 to 2034.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Bausch Health Companies (BHC)
-
Continued Strong Performance of Key Products: Bausch Health expects revenue growth from the sustained strong performance of established products such as Xifaxan and Thermage. Xifaxan, a gastroenterology product, saw an 11% revenue increase for the full year 2025, while Thermage, a medical aesthetic device under the Solta Medical segment, experienced a robust 19% revenue growth during the same period.
-
Global Expansion of Solta Medical: The Solta Medical segment, focusing on medical aesthetics, is a significant driver of future revenue growth, particularly through its expansion in international markets. This includes strong organic growth in regions like South Korea, which demonstrated 33% organic growth in Q1 2025, and China, where Bausch Health strategically acquired Shibo, a full-service aesthetics distribution platform, in December 2025 to strengthen its direct commercial presence.
-
Organic Growth Across Core Pharmaceutical Segments: Bausch Health anticipates continued organic revenue growth from its core pharmaceutical segments, including Salix, International Rx, and Diversified Products. The Salix segment, which focuses on gastroenterology products, and the International Rx segment have consistently delivered growth, contributing to the company's trend of multiple consecutive quarters of year-over-year revenue and adjusted EBITDA growth. The Diversified Products segment has also seen revenue increases, partially attributed to improved net pricing.
-
Strategic Acquisitions and Portfolio Enhancement: Future revenue growth is expected to be driven by strategic acquisitions that enhance Bausch Health's product portfolio and market presence. An example is the acquisition of DURECT Corporation, which is anticipated to bolster the company's expertise in hepatology and expand its treatment offerings for alcohol hepatitis. These targeted acquisitions aim to broaden the company's therapeutic areas and expand its market reach.
AI Analysis | Feedback
Share Repurchases
- Bausch Health Companies has not conducted significant share repurchases since 2017 due to its substantial debt burden.
- In the first quarter of 2025, management indicated the possibility of resuming share buybacks once the debt burden is normalized.
Share Issuance
- In May 2022, Bausch Health's subsidiary completed the initial public offering (IPO) of Bausch + Lomb, selling 35,000,000 common shares at $18.00 per share, generating aggregate gross proceeds of $630 million.
- Following the Bausch + Lomb IPO, Bausch Health and its subsidiaries retained approximately 90% of the common shares of Bausch + Lomb (or 88.5% if the underwriters' over-allotment option was exercised in full).
- From 2023-2025, BHC completed targeted secondary sales of Bausch + Lomb (BLCO) shares to reduce leverage and improve balance sheet flexibility.
Inbound Investments
- Paulson & Co. Inc. increased its investment in Bausch Health during the fourth quarter of 2025.
- As of August 15, 2025, Paulson Capital Inc. and certain affiliates and managed funds beneficially owned approximately 19.13% of the Company's outstanding common shares, which included the acquisition of 34,721,118 common shares previously held by Carl C. Icahn and his affiliates.
Outbound Investments
- On December 1, 2025, Bausch Health completed the acquisition of Shibo's full-service aesthetics distribution business in China.
- In the third quarter of 2025, the company completed the acquisition of DURECT Corporation, expanding Bausch Health's hepatology portfolio with the addition of Larsucosterol.
Capital Expenditures
- Bausch Health's annual capital expenditures were $397 million in 2025, $337 million in 2024, $215 million in 2023, $218 million in 2022, and $269 million in 2021.
- Capital expenditures are expected to be moderate, ranging from 3.1-3.7% of revenue, with a projected slight increase after 2028 to support new projects.
- The primary focus of capital expenditures includes investments in research and development initiatives, direct-to-consumer advertising, new sales force capabilities, and the global growth of segments like Solta Medical.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 126.63 |
| Mkt Cap | 275.2 |
| Rev LTM | 63,066 |
| Op Inc LTM | 18,176 |
| FCF LTM | 9,926 |
| FCF 3Y Avg | 5,217 |
| CFO LTM | 16,232 |
| CFO 3Y Avg | 11,337 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.0% |
| Rev Chg 3Y Avg | 4.0% |
| Rev Chg Q | 10.8% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 26.2% |
| Op Inc Chg 3Y Avg | 17.9% |
| Op Mgn LTM | 25.6% |
| Op Mgn 3Y Avg | 22.9% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 21.3% |
| CFO/Rev 3Y Avg | 19.0% |
| FCF/Rev LTM | 14.7% |
| FCF/Rev 3Y Avg | 13.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 275.2 |
| P/S | 4.1 |
| P/Op Inc | 20.5 |
| P/EBIT | 17.8 |
| P/E | 23.2 |
| P/CFO | 15.7 |
| Total Yield | 3.4% |
| Dividend Yield | 2.6% |
| FCF Yield 3Y Avg | 5.5% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.3% |
| 3M Rtn | -0.3% |
| 6M Rtn | 7.9% |
| 12M Rtn | 37.0% |
| 3Y Rtn | 73.7% |
| 1M Excs Rtn | 2.0% |
| 3M Excs Rtn | -9.9% |
| 6M Excs Rtn | -0.2% |
| 12M Excs Rtn | 13.3% |
| 3Y Excs Rtn | -3.0% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA216632 | CABTREO | adapalene | gel | 10202023 | 11.3% | 18.7% | 11.5% | -17.3% | -26.6% |
| NDA211882 | ARAZLO | tazarotene | lotion | 12182019 | -55.4% | -32.0% | -27.5% | -14.7% | -81.6% |
| NDA209354 | DUOBRII | halobetasol propionate | lotion | 4252019 | -0.9% | -4.5% | -28.7% | 25.0% | -77.4% |
| NDA209355 | BRYHALI | halobetasol propionate | lotion | 11062018 | -3.7% | -4.6% | -3.9% | -37.4% | -79.9% |
| NDA203567 | JUBLIA | efinaconazole | solution | 6062014 | -6.1% | 13.7% | 84.7% | -77.3% | -95.8% |
| NDA204153 | LUZU | luliconazole | cream | 11142013 | 33.9% | 17.2% | 26.8% | -28.8% | -94.9% |
| ANDA090715 | FENOFIBRATE | fenofibrate | tablet | 4052012 | -14.5% | 4.0% | 31.1% | 127.7% | -90.2% |
| NDA022483 | ZYCLARA | imiquimod | cream | 3252010 | 26.6% | 57.9% | 178.5% | 233.3% | -66.7% |
| NDA022436 | XERESE | acyclovir | cream | 7312009 | 14.0% | 29.7% | 118.3% | 439.5% | -47.4% |
| NDA050819 | ACANYA | benzoyl peroxide | gel | 10232008 | 19.3% | -3.3% | 68.9% | 257.5% | -24.1% |
| ... | |||||||||
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharmaceuticals | 4,396 | 3,909 | 3,642 | 3,763 | |
| Devices | 2,240 | 1,997 | 1,872 | 1,903 | |
| Over-the-counter (OTC) | 1,903 | 1,797 | 1,619 | 1,532 | |
| Branded and Other Generics | 979 | 960 | 892 | 1,144 | |
| Other revenues | 107 | 94 | 99 | 92 | |
| Bausch + Lomb | 3,415 | ||||
| Diversified | 979 | ||||
| International Rx | 1,181 | ||||
| Ortho Dermatologics | 548 | ||||
| Salix | 1,904 | ||||
| Total | 9,625 | 8,757 | 8,124 | 8,434 | 8,027 |
Price Behavior
| Market Price | $5.37 | |
| Market Cap ($ Bil) | 2.0 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -35.6% | |
| 50 Days | 200 Days | |
| DMA Price | $5.48 | $6.22 |
| DMA Trend | down | down |
| Distance from DMA | -2.0% | -13.7% |
| 3M | 1YR | |
| Volatility | 40.3% | 50.0% |
| Downside Capture | 97.89 | 67.40 |
| Upside Capture | 62.74 | 66.53 |
| Correlation (SPY) | 50.0% | 21.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.95 | 1.13 | 1.44 | 1.25 | 0.91 | 0.98 |
| Up Beta | 4.06 | 2.11 | 2.31 | 2.03 | 1.16 | 0.92 |
| Down Beta | 0.23 | 1.30 | 1.53 | 1.32 | 1.18 | 1.50 |
| Up Capture | -46% | 15% | 57% | 52% | 63% | 26% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 9 | 22 | 32 | 59 | 119 | 362 |
| Down Capture | 93% | 87% | 148% | 124% | 81% | 98% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 19 | 31 | 63 | 124 | 371 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BHC | |
|---|---|---|---|---|
| BHC | 20.0% | 49.9% | 0.53 | - |
| Sector ETF (XLV) | 16.9% | 15.0% | 0.83 | 32.9% |
| Equity (SPY) | 25.3% | 12.1% | 1.57 | 20.1% |
| Gold (GLD) | 27.6% | 26.9% | 0.88 | 9.3% |
| Commodities (DBC) | 36.9% | 19.0% | 1.52 | -8.9% |
| Real Estate (VNQ) | 12.5% | 13.3% | 0.63 | 20.3% |
| Bitcoin (BTCUSD) | -39.7% | 42.2% | -1.08 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BHC | |
|---|---|---|---|---|
| BHC | -29.6% | 60.4% | -0.33 | - |
| Sector ETF (XLV) | 6.1% | 14.7% | 0.23 | 30.8% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 34.7% |
| Gold (GLD) | 17.3% | 18.1% | 0.78 | 1.4% |
| Commodities (DBC) | 9.5% | 19.4% | 0.38 | 6.2% |
| Real Estate (VNQ) | 3.2% | 18.8% | 0.07 | 30.4% |
| Bitcoin (BTCUSD) | 12.1% | 54.6% | 0.42 | 16.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BHC | |
|---|---|---|---|---|
| BHC | -14.6% | 60.0% | -0.00 | - |
| Sector ETF (XLV) | 9.9% | 16.6% | 0.48 | 37.0% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 39.3% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 1.1% |
| Commodities (DBC) | 7.1% | 18.0% | 0.32 | 15.0% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 32.4% |
| Bitcoin (BTCUSD) | 63.9% | 66.9% | 1.03 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | 2.3% | 1.1% | -4.1% |
| 2/18/2026 | -4.2% | -1.3% | -18.7% |
| 10/29/2025 | 12.0% | 14.9% | 19.5% |
| 7/30/2025 | -7.8% | -9.9% | 11.9% |
| 4/30/2025 | 0.0% | -11.3% | -14.5% |
| 2/19/2025 | 10.3% | 18.3% | 9.5% |
| 10/30/2024 | 12.6% | 16.3% | 2.4% |
| 8/1/2024 | 1.2% | -13.4% | -2.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 11 | 12 |
| # Negative | 12 | 13 | 12 |
| Median Positive | 5.5% | 7.5% | 10.5% |
| Median Negative | -8.6% | -10.6% | -15.1% |
| Max Positive | 14.0% | 18.3% | 28.3% |
| Max Negative | -27.1% | -19.7% | -30.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 10.67 Bil | 10.79 Bil | 10.92 Bil | 0.4% | Raised | Guidance: 10.75 Bil for 2026 | |
| 2026 Revenue Growth | 2.0% | 3.5% | 5.0% | 0 | 0 | Affirmed | Guidance: 3.5% for 2026 |
| 2026 Adjusted EBITDA | 3.88 Bil | 3.95 Bil | 4.01 Bil | 0.3% | Raised | Guidance: 3.94 Bil for 2026 | |
| 2026 Adjusted EBITDA Growth | 3.0% | 4.0% | 5.0% | 0 | 0 | Affirmed | Guidance: 4.0% for 2026 |
| 2026 Adjusted Cash Flow from Operations | 1.20 Bil | 1.24 Bil | 1.27 Bil | 0 | Affirmed | Guidance: 1.24 Bil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/18/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 10.62 Bil | 10.75 Bil | 10.88 Bil | 5.9% | Higher New | Actual: 10.15 Bil for 2025 | |
| 2026 Revenue Growth | 2.0% | 3.5% | 5.0% | ||||
| 2026 Adjusted EBITDA | 3.88 Bil | 3.94 Bil | 4.00 Bil | 8.9% | Higher New | Actual: 3.62 Bil for 2025 | |
| 2026 Adjusted EBITDA Growth | 3.0% | 4.0% | 5.0% | ||||
| 2026 Adjusted Operating Cash Flow | 1.20 Bil | 1.24 Bil | 1.27 Bil | ||||
Insider Activity
Updated 5/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lee, Frank D | Direct | Sell | 5202026 | 5.43 | 24,456 | 132,796 | 267,911 | Form | |
| 2 | Carson, Seana | EVP, General Counsel | Direct | Sell | 2272026 | 5.95 | 8,388 | 49,909 | 4,815,085 | Form |
| 3 | Paulson, & CO Inc | Managed Funds | Buy | 11282025 | 6.25 | 2,500,000 | 15,625,000 | 457,849,181 | Form | |
| 4 | Carson, Seana | EVP, General Counsel | Direct | Sell | 9082025 | 7.31 | 13,370 | 97,735 | 3,651,966 | Form |
| 5 | Lee, Frank D | Direct | Sell | 8222025 | 7.66 | 15,912 | 121,886 | 565,270 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.